Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

IQVIA HOLDINGS INC.

(IQV)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Piper Sandler Adjusts Price Target on IQVIA Holdings to $261 From $250, Maintains Neutral Rating

11/18/2021 | 06:55am EST


© MT Newswires 2021
All news about IQVIA HOLDINGS INC.
01/04Travere Therapeutics Names Jula Inrig Chief Medical Officer
MT
01/04Evercore ISI Adjusts Price Target for IQVIA Holdings to $350 From $320, Maintains Outpe..
MT
2021Mizuho Securities Adjusts IQVIA Holdings PT to $300 From $290, Maintains Buy Rating
MT
2021IQVIA : OneKey Powers Precision Targeting
PU
2021Dr. Reddy's Laboratories Releases Generic Version of Osmotica's Venlafaxine Tablets
MT
2021Global Medicine Spending to Reach $1.8 Trillion in 2026, Including Spending on COVID-19..
BU
2021Aslan Pharmaceuticals Working With Iqvia Biotech on Clinical Trials
MT
2021ASLAN Pharmaceuticals and IQVIA Biotech Enter Into Strategic Collaboration
AQ
2021ASLAN Pharmaceuticals and IQVIA Biotech Enter Into Strategic Collaboration
CI
2021IQVIA Decentralized Trial Suite Launches Mobile Research Nursing and Phlebotomy Service..
BU
More news
Analyst Recommendations on IQVIA HOLDINGS INC.
More recommendations
Financials (USD)
Sales 2021 13 830 M - -
Net income 2021 922 M - -
Net Debt 2021 10 634 M - -
P/E ratio 2021 50,9x
Yield 2021 -
Capitalization 46 031 M 46 031 M -
EV / Sales 2021 4,10x
EV / Sales 2022 3,73x
Nbr of Employees 77 000
Free-Float 74,2%
Chart IQVIA HOLDINGS INC.
Duration : Period :
IQVIA Holdings Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IQVIA HOLDINGS INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 19
Last Close Price 240,95 $
Average target price 304,59 $
Spread / Average Target 26,4%
EPS Revisions
Managers and Directors
Ari Bousbib Chairman, President & Chief Executive Officer
Ronald Earl Bruehlman Chief Financial Officer & Executive Vice President
Karl Guenault Chief Information Officer & Senior Vice President
W. Richard Staub President-Research & Development Solutions
Kevin C. Knightly President-Technology & Commercial Solutions
Sector and Competitors
1st jan.Capi. (M$)
IQVIA HOLDINGS INC.-14.60%46 031
MODERNA, INC.-36.98%64 900
LONZA GROUP AG-15.65%52 307
SEAGEN INC.-17.50%23 323
ICON PUBLIC LIMITED COMPANY-18.65%20 508
CELLTRION, INC.-17.42%19 126